We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
McKesson (MCK) Misses Earnings Estimates in Q1, Raises View
Read MoreHide Full Article
McKesson Corporation (MCK - Free Report) reported first-quarter fiscal 2018 (ended Jun 30, 2017) earnings of $2.46 per share, missing the Zacks Consensus Estimate of $2.81. Earnings also lagged the year-ago figure of $3.15. Performance was muted owing to branded to generic conversions and steep competition in its pharmacy business.
Revenues improved 3% year over year to $51.1 billion but failed to meet the Zacks Consensus Estimate of $51.2 billion.
Quarter in Detail
McKesson operates through two segments, Distribution Solutions and Technology Solutions. All growth rates given below are on a year-over-year basis.
At Distribution Solutions, revenues increased 5% to $50.9 billion. North America pharmaceutical distribution and services reported sales of $43.0 billion, up 5% on market growth and acquisitions. Revenues were hit by branded to generic conversions. Revenues from International pharmaceutical distribution and services were up 6% to $6.4 billion. Medical-Surgical distribution and services generated sales of $1.5 billion, up 4%.
However, revenues from the Technology Solutions business fell from $724 million in the year-ago quarter to $120 million. This was due to the bifurcation of the Technology Solutions businesses to the Change Healthcare joint venture on Mar 1. The segment reflects only the numbers from the Enterprise Information Solutions business.
McKesson Corporation Price, Consensus and EPS Surprise
As of Jun 30, McKesson had $2.3 million in cash and cash equivalents against $2.8 million as of Mar 31. During the reported quarter (ended Jun 30, 2017), the company generated cash amounting to $741 million from operations. Also in fiscal 2017, McKesson paid $1.5 billion for acquisitions, repurchased $250 million of its common stock, repaid approximately $541 million in long-term debt and paid $62 million in dividends.
Fiscal 2018 Outlook
McKesson expects GAAP earnings per diluted share of $7.10 to $9.00 for the fiscal ending Mar 31, 2018. Adjusted earnings for the same period are expected in the range of $11.80 to $12.50 per diluted share. Distribution Solutions business revenue growth is expected to increase by mid-single digits year over year. The upside is expected to be driven by market growth and acquisitions. Revenues from Technology Solutions are expected to be down on a year-over-year basis.
Zacks Rank & Key Picks
McKesson currently carries a Zacks Rank #3 (Hold). A few better-ranked medical stocks are Mesa Laboratories, Inc. (MLAB - Free Report) , INSYS Therapeutics, Inc. and Align Technology, Inc. (ALGN - Free Report) . Notably, INSYS Therapeutics sports a Zacks Rank #1 (Strong Buy), while Mesa Laboratories and Align Technology carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
INSYS Therapeutics has a long-term expected earnings growth rate of 20%. The stock has gained around 5.7% over the last three months.
Mesa Laboratories has a positive earnings surprise of 2.84% for the last four quarters. The stock has added roughly 4.1% over the last three months.
Align Technology has an expected long-term adjusted earnings growth of almost 24.1%. The stock has added roughly 32.1% over the last three months.
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.
Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
McKesson (MCK) Misses Earnings Estimates in Q1, Raises View
McKesson Corporation (MCK - Free Report) reported first-quarter fiscal 2018 (ended Jun 30, 2017) earnings of $2.46 per share, missing the Zacks Consensus Estimate of $2.81. Earnings also lagged the year-ago figure of $3.15. Performance was muted owing to branded to generic conversions and steep competition in its pharmacy business.
Revenues improved 3% year over year to $51.1 billion but failed to meet the Zacks Consensus Estimate of $51.2 billion.
Quarter in Detail
McKesson operates through two segments, Distribution Solutions and Technology Solutions. All growth rates given below are on a year-over-year basis.
At Distribution Solutions, revenues increased 5% to $50.9 billion. North America pharmaceutical distribution and services reported sales of $43.0 billion, up 5% on market growth and acquisitions. Revenues were hit by branded to generic conversions. Revenues from International pharmaceutical distribution and services were up 6% to $6.4 billion. Medical-Surgical distribution and services generated sales of $1.5 billion, up 4%.
However, revenues from the Technology Solutions business fell from $724 million in the year-ago quarter to $120 million. This was due to the bifurcation of the Technology Solutions businesses to the Change Healthcare joint venture on Mar 1. The segment reflects only the numbers from the Enterprise Information Solutions business.
McKesson Corporation Price, Consensus and EPS Surprise
McKesson Corporation Price, Consensus and EPS Surprise | McKesson Corporation Quote
Financial Condition
As of Jun 30, McKesson had $2.3 million in cash and cash equivalents against $2.8 million as of Mar 31. During the reported quarter (ended Jun 30, 2017), the company generated cash amounting to $741 million from operations. Also in fiscal 2017, McKesson paid $1.5 billion for acquisitions, repurchased $250 million of its common stock, repaid approximately $541 million in long-term debt and paid $62 million in dividends.
Fiscal 2018 Outlook
McKesson expects GAAP earnings per diluted share of $7.10 to $9.00 for the fiscal ending Mar 31, 2018. Adjusted earnings for the same period are expected in the range of $11.80 to $12.50 per diluted share. Distribution Solutions business revenue growth is expected to increase by mid-single digits year over year. The upside is expected to be driven by market growth and acquisitions. Revenues from Technology Solutions are expected to be down on a year-over-year basis.
Zacks Rank & Key Picks
McKesson currently carries a Zacks Rank #3 (Hold). A few better-ranked medical stocks are Mesa Laboratories, Inc. (MLAB - Free Report) , INSYS Therapeutics, Inc. and Align Technology, Inc. (ALGN - Free Report) . Notably, INSYS Therapeutics sports a Zacks Rank #1 (Strong Buy), while Mesa Laboratories and Align Technology carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
INSYS Therapeutics has a long-term expected earnings growth rate of 20%. The stock has gained around 5.7% over the last three months.
Mesa Laboratories has a positive earnings surprise of 2.84% for the last four quarters. The stock has added roughly 4.1% over the last three months.
Align Technology has an expected long-term adjusted earnings growth of almost 24.1%. The stock has added roughly 32.1% over the last three months.
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.
Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>